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Summary
Objectives: To estimate the incidence of rabies and the effectiveness of post-
exposure treatment (PET) in Pakistan.
Methods: Rabies cases admitted from July 1993 to December 1994 to a public rabies
isolation hospital were analyzed. Two samples (one sample each from a separate
peripheral site) of a single batch of sheep brain vaccine (SBV) were also tested for
potency by the National Institute of Health (NIH) test in May 1997.
Results: Forty patients were admitted with a history of clinical rabies. The median
age was 22 years and 55% were under 15. Thirteen (23%) victims did not receive any
vaccine; the remaining 27 (67%) received SBV only, and of these, 16 (40%) received a
full course of SBV. No rabies immunoglobulins (RIG) or cell culture vaccines were
administered. There were frequent power blackouts and no back-up supply at the
public hospital. In-house potency testing of the vaccine batch by the manufacturer
was adequate, athough it was not tested by the World Health Organization (WHO)
recommended NIH test. Samples of SBV of the same batch collected at the peripheral
sites showed no potency. Rabies incidence was estimated to range between 7.0 to 9.8
cases per million annually.
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Tel.: +1 304 846 2573; fax: +1 304 846 9562.
E-mail address: sparviz19@hotmail.com (S. Parviz).
1201-9712/$30.00 # 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2004.02.008
Introduction
Rabies continues to be a public health hazard in at
least 87 countries.1 Despite its preventability, rabies
accounts for an estimated 50,000 human deaths
each year, mostly in developing countries.2 Bogel
and Motschwiller (1986),1 using 1979 data, esti-
mated that India (28.8 per million), Ethiopia (12.6
per million), Sri Lanka (10.2 per million), Argentina
(8.2 per million) and Thailand (7.2 per million) had
the highest incidence rates.
Although rabies mortality approaches 100% once
clinical signs set in, prompt debridement of the
wound, infiltration of the wound site with rabies
immune globulin (RIG) and administration of a
potent vaccine (World Health Organization (WHO)
expert committee 1992) will serve as a successful
antidote against a severe exposure.3 Vaccinating
dogs against rabies, applying leash and dog owner-
ship laws and removing stray dogs, can also sub-
stantially reduce the risk to humans.4 The success of
rabies control in Europe and North America has been
due to the control of stray dogs, vaccinating sus-
ceptible wildlife, and wide use of post-exposure
treatment (PET).4 Lack of resources and technical
expertise and the inability to control an increasing
stray dog population has resulted in less effective
control of rabies in Pakistan. In addition, many low-
income countries rely on the inexpensive, some-
times locally produced, less efficacious nerve tissue
vaccines, such as sheep brain vaccine (SBV) rather
than the more effective tissue culture vaccine.3
Regrettably, in these circumstances RIG is only
rarely administered.3
Sheep brain vaccine (SBV), in addition to having
poorer efficacy compared to cell culture rabies
vaccines, is associated with neuroparalytic reac-
tions reported at a rate of at least one in 200
vaccinees.5 These range from peripheral neuropa-
thy, myelitis, meningoradiculitis, paraplegia and
encephalitis to Guillian Barre´ syndrome and
are due to the immunological reaction to myelin
basic protein in SBV.5—8 There is also a high dropout
rate (33%) since giving SBV entails multiple
(at least 14) painful injections in the abdominal
wall.9
The National Institute of Health (NIH) in Pakistan
produces all of the anti-rabies SBV in Pakistan. This
is purchased by the provincial governments and
provided free of charge to the general public. The
recommended regimen is to give 2 ml of the 5% SBV
suspension subcutaneously in adults and 1.5 ml in
children under 12 years of age consecutively for 14
days and then a booster on days 24, 34 and 104.
Pakistan’s NIH also produces unpurified equine RIG
in small quantities. Various imported rabies biolo-
gicals available10 at the time of the study included
purified Vero cell vaccine (PVRV; VerorabTM, Pasteur
Merieux Connaught); purified duck embryo vaccine
(PDEV; Lyssavac-NTM, Berna Swiss and Serum Insti-
tute, Switzerland); purified equine rabies immuno-
globulin (ERIG; Swiss Serum and Vaccine, Institute
Berne, Switzerland and bioMerieux, Marcy L’Etiole,
France) and human rabies immunoglobulin (HRIG;
Bayer, West Haven, CT, USA). These can be pur-
chased commercially by those who can afford them.
Note that both the PDEV and the ERIG above are no
longer produced.
Although Pakistan’s neighbour, India, accounts
for 60% of all reported rabies mortality worldwide,
there are no incidence estimates from Pakistan.2
Thus, a study was conducted to estimate the inci-
dence of rabies in Karachi and evaluate what pro-
portion of rabies victims had been vaccinated with
full or partial courses of SBV.
Methods
Karachi is the largest city in Pakistan with a popula-
tion of 9.3 million (census of 1998).11 Civil Hospital
(CHK), a government referral hospital, has the only
rabies isolation ward in Karachi. The medical
records of all the patients admitted with clinical
rabies from July 1993 to December 1994 were
reviewed. Rabies was clinically diagnosed in
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Conclusion: A multi-sectorial approach is needed to decrease rabies incidence in
Pakistan. Public and healthcare practitioner education on prompt and appropriate
PET, especially the use of cost-effective cell culture intradermal regimens, is needed
urgently. The NIH test should be employed for vaccine potency testing. An indepen-
dent agency is needed for monitoring vaccine quality and strategies are needed for
maintaining cold chain. SBV should be replaced by locally manufactured second-
generation cell culture rabies vaccine. Purified equine rabies immunoglobulin (ERIG)
should be manufactured locally to meet national needs. Furthermore, effective dog
control strategies should be implemented to decrease the rabies reservoir.
# 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
patients with agitation, hydrophobia and a history of
dog bite. Laboratory confirmation was not available.
Data were extracted on the demographic features of
the patients, clinical signs and symptoms, history of
dog bite and post-exposure treatment. PET was
compared with WHO standards, which consist of
the immediate scrubbing of the wound with water
and soap, irrigating it with a viricidal agent (20%
soap solution, povidine-iodine, 0.1% aqueous iodine
or 40—70% alcohol), potent cell culture vaccine
[given in five intramuscular (IM) shots (Essen regi-
men), four IM shots (Zagreb regimen 211), or
reduced dose intradermal (ID) regimens (TRC
222011 and Warrell 804011)] and RIG for transder-
mal bites and mucosal exposures, and vaccine only
for minor scratches and abrasions.3 TRC 222011
consists of id injections at two different sites on
day 0, 3, 7 and one site on day 28 and 90 of exposure
while the Warrell 804011 consists of id injections at
8 different sites on day 0, four sites on day 7 and one
site on day 28 and 90 of exposure. Current vaccines
approved for TRC 222011 regimen by WHO are HDCV
(RabivacTM) and purified chick embryo cell vaccine
(PCEV) (RabipurTM). Current vaccines approved for
the Warell 804011 regimen by WHO are PVRV (Ver-
orabTM, ImovaxTM, Rabies veroTM, TRC VerorabTM)
and PCEV (RabipurTM).
The nursing personnel and staff physicians at CHK
were interviewed to obtain the proportion of victims
clinically diagnosed with rabies but who did not
request admission after knowing about the grave
prognosis. The annual number of rabies cases was
estimated by dividing the number of observed
cases with the proportion of the victims seeking
admission. Karachi’s population was calculated for
1994 by using the census figures and compound
annual growth rate (3.49%) between 1981 (pop.
5,208,132) and 1998 (pop. 9,339,023).11 The pro-
jected population was calculated by using the
formula12: projected population = initial population
X (1 + growth rate)number of years.
Information from Pakistan’s NIH was obtained
regarding its vaccine production. After noticing a
very high proportion of rabies victims failing with
SBV, we collected two vials of SBV of the same batch
(#420) in May 1997 from the two largest public
hospitals in Karachi: Jinnah Post-graduate Medical
Center and CHK. These vials were obtained from a
storage refrigerator kept at 4 8C in the respective
hospitals; the batch was being used for PET. The
samples were placed in a cooling container packed
with insulating material and ice, and transported by
air to Aventis-Pasteur, Lyon, France (an interna-
tional manufacturer of rabies vaccine) for potency
testing by the National Institute of Health (NIH)
test.13
Results
In the 18 months between July 1993 and December
1994, 40 patients clinically diagnosed with rabies
were admitted to the isolation ward of CHK. Thirty-
four (85%) were males. Their median age was 22
years; 22 (55%) were under 15 years of age. All 40
patients had symptoms of agitation and hydropho-
bia. In addition, 28 patients (70%) had at least two
other neurological symptoms, most commonly anxi-
ety and dysphagia. All had a history of dog bite in the
year prior to the onset of illness, 20 (50%) within the
preceding 30 days. Fifteen (37.5%) were from Kar-
achi’s East district, 11 (27.5%) were from West
district, three (7.5%) were from Central district,
and one (2.5%) from South district. In five cases
(12.5%) residence could not be determined and five
(12.5%) were outside Karachi limits.
Of the 14 individuals who had documentation in
their medical records of where on the body they had
been bitten, seven (50%) had been bitten on the
face, three (21%) on the leg, three (21%) on the
hands, and one on both head and arm. Of the seven
individuals who had been bitten on the face, five
(71%) presented within one month, which is consis-
tent with the shorter incubation period from bites in
close proximity to the central nervous system.14 In
these records there was no documentation of wound
care after the bite.
Twenty-seven rabies victims (67%) had received
PETwith a rabies vaccine, which was SBV in all cases.
None had received the rabies cell culture vaccine.
Sixteen (40%) completed a full course of SBV, con-
sisting of 17 injections. Among the 11 victims who
received incomplete vaccination, one person
received 12 doses, while the rest received five doses
or less. None of the 27 received RIG after the dog
bite. Sixteen (40%) of the victims died of rabies
while in the isolation unit; the other 24 were
taken home by their families after learning the
poor prognosis.
Among the 40 rabies cases, 30 were confirmed as
having lived within Karachi city limits. Based on
interviews at the CHK’s emergency room and dis-
cussion with medical staff at the other large govern-
ment hospital in the city that dispenses rabies
vaccine, it is estimated that 25—35% of all children
presenting with a syndrome and history consistent
with classical rabies were admitted to the CHK’s
rabies isolation ward. Thus these 30 deaths would
represent 86 to 120 deaths in Karachi during the 18
months of this study (30/0.25—0.35) and would
equate to 57 to 80 deaths in a year. Using the
formula for the projected population (see Methods
section), the estimated population of Karachi in
1994 was 8.1 million inhabitants. The estimated
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incidence of human rabies deaths in Karachi ranged
from 7.0 to 9.8 cases per million per year.
After contacting NIH, it was found out that SBV is
a killed vaccine prepared from sheep brain tissue
infected with fixed rabies virus and inactivated with
phenol at 37 8C. The final vaccine is 5% brain tissue
suspension with 0.5% phenol and hence does not
require reconstitution. After it is manufactured, it is
kept in cold rooms at 4 8C and is transported by air
on ice packs maintaining temperature for 24 hours.
It was noticed that there were frequent power cuts
at CHK, without backup for maintaining the cold
chain. NIH has a National Quality Control Laboratory
which tests each batch for sterility, safety, potency,
phenol content and toxicity before it is released.
The two vials of batch #420 of SBV that had been
collected during May 1997 from peripheral sites did
not show any protection when tested with the
NIH test for potency. At the NIH, 45 of 1580 vials
of the batch were tested for potency by the Habel
test13 before release and the vaccine titer was
3.181 IU/ml (the minimum potency requirement
set by NIH is 3.1 IU/ml).
Discussion
Our estimated incidence of human rabies in Karachi,
Pakistan, is consistent with the high incidence of
rabies in South-East Asia. The sheep brain vaccine
(SBV), which is the cornerstone of rabies prevention
in Karachi, is ineffective. There is a lack of con-
trolled trials looking at the efficacy of SBV. Indian-
produced SBVof the 1950s had an estimated efficacy
of 84% in completely treated patients, which
dropped to 58% in incompletely treated patients
(the data were based on a retrospective analysis
of infected dog bites).15
Although SBV has some efficacy against rabies
exposures and has saved many lives, it becomes
useless in severe exposures when protection is most
needed.16 The figure found here, of 40% of rabies
victims acquiring rabies, despite complete vaccine
regimen, is higher than Burney et al.’s previous
estimate in Karachi in the mid 1960s of 23% and
from previous studies in Thailand and India of 11%
and 6.5% respectively.15,17,18 In India, an increasing
SBV dosage is given depending upon the severity of
exposure (four times the adult dose of phenol-inac-
tivated Indian SBV is recommended for severe expo-
sures compared to minor exposures and Pakistan’s
SBV recommended adult dose).19 Burney et al
reported in the 1960s that after a full course of
Pakistan’s SBV, only 50% of the vaccinated patients
achieved neutralizing antibodies.17 Similarly in
Thailand, in a randomized trial by Warrell et al of
Thailand’s SBV vs. human diploid cell vaccine
(HDCV) with RIG, given when indicated, protective
antibody titers were present in 42% vs. 100% at day
14, and 6% vs. 100% at one year.20 Furthermore, the
immune response after SBV is not long lasting.21
WHO recommends all countries producing rabies
nerve tissue vaccine to shift to the cell culture
vaccine.3 Yet SBV is still the most common rabies
vaccine used in developing countries, where better
vaccines are most needed (in India 700,000 people
received SBV in 1997).22
The other deficiencies in PET in our study limit-
ing rabies prevention in Karachi were (1) no post-
exposure vaccination as nearly a quarter did not
receive any vaccine (2) low compliance with the SBV
vaccination schedule with more than half receiving
an incomplete course (3) no use of RIG and (4)
inability to maintain the cold chain, which was also
seen in the dog bite study.10 Factors that could not
be assessed from the study but that might have
played a role include (5) inadequate and inappropri-
ate wound care as seen in the previous dog bite
study10 in which wounds of 69% of 143 dog bite
victims were not cleansed with soap, iodine or
alcohol, thus failingWHO standards3 and (6) possible
delays in initiating PET.23 The last factor was corro-
borated with a randomized community survey of
households in a squatter settlement in Karachi dur-
ing the same period as the study, in which 23% of
respondents with a dog bite in the household did not
go to a hospital for care. Among those who went to
hospital, 31% did not complete the full course of
vaccination (Noorudeen Punjwani, The Aga Khan
University; personal communication).
The WHO recommends, for rabies-endemic
developing countries, the use of second-generation
tissue culture vaccines like purified chick embryo
(PCEV) and purified vero cell (PVRV) in cost-effec-
tive ID regimens.3 Dog bite victims can be vacci-
nated intradermally (ID) with these vaccines for as
little as US$ 30 at commercial prices in cost-effec-
tive regimens of ID TRC 222011 (PVRVand PCEV) and
ID Warrell 804011 (PCEV).20,24
In an unpublished study in Karachi (Khalid et al.
The Aga Khan University, 1997) the direct (at market
price) and indirect costs (loss of wages and trans-
portation costs, excluding failure rates with vaccine
and life lost) of ID vaccine regimens with PVRV was
cheaper than SBV. Thailand in the 1980’s, by adopt-
ing an ID cell culture vaccine regimen with RIG
strategy, decreased rabies incidence from 7.6 per
million in 1979 to 0.9 per million in 1997.1 Two
other developing countries Philippines and Sri-Lanka
have stopped nerve tissue vaccine production and
in 1997 adopted ID regimens using imported cell
culture vaccine. Similarly to Thailand, China has
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considerably reduced rabies incidence with the
availability of improved PET, namely by using ERIG
and primary hamster kidney cell vaccine (PHK)
that can be given in five shots intramuscularly.25,26
Pakistan’s neighbour, India is also gradually phasing
out its SBV production to cell culture vaccine. Three
out of 25 states have moved to using solely cell cul-
ture vaccine, consisting of PVRV and purified chick
embryo culture (PCEC) manufactured by a govern-
ment-funded company and a private company
respectively.27 Although ID regimens have not been
officially approved, studies have shown that ID regi-
mens are effective in the Indian population.28,29
The NIH in Pakistan was the first among develop-
ing countries to locally produce expensive freeze-
dried HDCV in 1988 but stopped production after five
years for political and technical reasons, though it
still has equipment for cell culture vaccine produc-
tion.30,31 Restarting production of one of the second
generation tissue culture vaccines like PVRV, which
is much cheaper than HDCV, would be within NIH’s
capacity.32 Local production will make the vaccine
cheaper and even more economical when given in
the ID regimens.
The fact that two randomly selected vials of SBV
from the NIH in Pakistan had no potency suggests
problems with either vaccine quality control/pro-
duction or cold chain at the peripheral sites. There
has been a report of a vaccine with no antigenic
value from Nigeria but that was a rabies vaccine of
unknown origin, purchased at an openmarket during
a vaccine shortage period.33 WHO recommends the
NIH test instead of the Habel test (which was used by
NIH Pakistan) for potency testing and calibration of
rabies vaccines.3 India and Bangladesh also use the
NIH test for SBV potency testing (personal commu-
nication: S.N. Madhusudana and Z. Ahmed respec-
tively). Pakistan does not have an independent
vaccine monitoring body. This raises the question
as to how other developing countries maintain qual-
ity control of their own biological products. An
external monitoring agency, such as the Food and
Drug Administration (FDA) in the USA, is essential for
vaccines, drugs and other biologicals.34 An interna-
tional agency for monitoring vaccines for developing
countries is another option. This would require
international prioritization, funding and coopera-
tion from the countries involved. Maintenance of
the cold chain is a major hurdle in developing
countries, especially at peripheral sites with
heat-intolerant SBV.35 Freeze dried HDCV tested
in Pakistani medical staff was stable for 11 weeks
at 26—37 8C.36 PCEV (Chiron Institute) is stable for
three months at 37 8C.37 Similarly, PHK, PDEV, PVRV
are likely to be more thermostable than SBV.35 This
is why replacing SBV with a freeze dried cell culture
vaccine would be a solution to the problem. Never-
theless, improved strategies to monitor and main-
tain cold chain are needed. These are major critical
public health challenges.
Although it has been known for over half a cen-
tury that RIG is critical in severe rabies wounds,
none of the patients received rabies immune glo-
bulin (RIG) because both commercially available
RIGs were expensive.38 HRIG was eight times more
expensive than ERIG (US$ 293 vs. 35 for an equiva-
lent dose for a 60 kg adult). Currently, there is a
shortage of ERIG worldwide as international manu-
facturers have stopped production because of com-
plex regulations, increasing production costs and
pressure from animal rights activists.39 In Thailand,
purified ERIG as well as HRIG (via plasmapharesis
from an adequate number of human donors) is
produced locally.40 Production of purified ERIG has
a substantial low cost yield that is effective for
human PET with very low risk of anaphylaxis and
hence should be carefully considered by NIH.41 In
India, locally produced ERIG costs US$ 15 for a 60 kg
adult. In the absence of RIG the IDWarrell regimen is
preferred as it produces an earlier neutralizing anti-
body response on day seven compared to IM Essen
and ID TRC-222011 regimens.20,24
Furthermore, failure of the simple but crucial
measure of proper wound care to reduce the viral
inoculum is not routinely observed in Karachi, as
noted previously.3,10 In a report detailing PET fail-
ures, the PET apparently failed, despite patients
receiving a proper tissue culture vaccine and RIG,
because none of their wounds were locally
cleansed.26 Public and health practitioner educa-
tion is essential regarding the dangers of dog bites
and the importance of prompt irrigation and cleans-
ing of wounds and applying antiviral agents like
povidine or alcohol as recommended by WHO.3
There are important limitations to this study. The
estimate of rabies incidence is imprecise; victims
might seek care at other hospitals and rabies might
be under-diagnosed because of the unknown num-
ber of elusive dumb or paralytic clinical presenta-
tions, which may account for up to 30% of rabies
cases.42 Some patients may have been misdiag-
nosed, because there was no access to laboratory
confirmation. There was also no follow-up record of
the 24 rabies victims who left the hospital after
learning the poor prognosis.
Rabies is, however, a clinically distinctive
disease, usually easily and accurately recognized
by physicians familiar with the condition and the
prognosis is virtually hopeless with only one fully
documented human survivor who remained severely
impaired neurologically.2,42 Overall, the estimates
reported here are consistent with reported
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incidences from neighboring countries in South Asia.
It could not be ascertained that the lack of potency
of the SBV vials tested was due to the failure of
maintaining cold chain or improper vaccine manu-
facturing/quality control, although the vaccine was
collected from two different hospitals. The exact
time from exposure to vaccination from patients’
records could not be determined due to lack of
documentation. The result of 40% of rabies victims
developing rabies despite a full course of SBV should
not be equated with vaccine efficacy or failure
rate as such an analysis requires knowledge of the
incidence of rabies in both vaccinated and unvacci-
nated groups.
Karachi has a high incidence of rabies deaths.
Ideally there needs to be a paradigm shift in canine
rabies-endemic countries towards an effective dog
control program which will decrease the virus reser-
voir, the demand for expensive PET, the number of
rabies deaths, and would be economical in the long
run.43,44 Unfortunately, canine control programs
have only been effective in a few countries in Asia
that have closed borders i.e. peninsular Malaysia
and Singapore.2,45 Canine control programs also
require multi-sectorial coordination, years of imple-
mentation to accrue economic benefits and are
costly at inception.43,44 Still, an ineffective and
obsolete vaccine wastes scarce resources, undercuts
professional motivation, erodes public confidence
and costs lives, especially when cost-effective alter-
natives are available.
Indeed many things need to be done but because
of other priority infectious diseases, low health
expenditure, particularly on public health and
external debt, resources need to be tapped and
strategies prioritized. To save human lives the most
cost-effective and foremost step would be educat-
ing the general public and healthcare physicians
regarding prompt, appropriate wound care and
rabies PET. We should educate and train health
care physicians, especially those at government-
approved rabies PET centers, about the option of
cheaper cell culture intradermal regimens. This
would increase awareness and use of these regimens
as well as exerting pressure on national authorities
to eventually change to cell culture vaccine produc-
tion. Vaccine potency testing by the manufacturer
has to be undertaken with the WHO-approved NIH
test. An independent agency for monitoring locally
produced and imported vaccines would be essential
for ensuring safe and effective vaccines. Strategies
are needed for monitoring compliance of cold chain.
SBV needs to be phased out and replaced by second
generation rabies cell culture vaccine production
and the existing RIG facility should be upgraded
to produce sufficient amounts of purified ERIG.
Availability of better PET will still not obviate the
need for effective and coordinated strategies to
control canine rabies. These need to be planned
and implemented to eliminate rabies in the long
term.
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